Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for Brimochol PF for the Treatment of Presbyopia

Follow Drugslib on

Generic name: brimonidine tartrate and carbachol Treatment for: Presbyopia

Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for Brimochol PF for the Treatment of Presbyopia

LONDON, United Kingdom and SEATTLE, Wash., June 03, 2025 – Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Brimochol PF for the treatment of presbyopia. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026, for Brimochol PF. The FDA noted that it is not planning to hold an advisory committee meeting to discuss this application.

Tenpoint Therapeutics’ management, including Henric Bjarke, Chief Executive Officer, Ben Bergo, President & Chief Business Officer, and Melissa Epperly, Chief Financial Officer will participate at the Jefferies Global Healthcare Conference in New York from June 3 - 4, 2025.

“This milestone marks a significant step forward in our transition toward becoming a commercial-stage company, and we look forward to collaborating closely with the Agency throughout the review process,” said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. “As the only combination product of its kind, BRIMOCHOL™ PF offers the potential for a best-in-class product, achievable through a unique and differentiated profile. With our commercial leadership team now in place, we are fully engaged in launch preparations as we anticipate a product availability in 1H 2026.”

About Tenpoint Therapeutics

Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. Its lead asset, Brimochol™ PF, is a novel pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for Brimochol™ PF and has submitted an NDA to the US FDA. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Business Bank (formerly British Patient Capital), Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and Wille AG.

Source: Tenpoint Therapeutics Ltd.

Posted : 2025-06-11 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords